Indivi raises CHF 15 M

Indivi develops digital biomarkers that turn smartphones and everyday devices into measurement tools for neuroscience drug development. The CHF 15 million capital increase will fund, from 2026, a proof-of-concept trial in Alzheimer's disease.

Announced on
Round
Undisclosed round
Amount
CHF 15 M
Location
Basel, canton of Basel-Stadt
Sector
Health & medtech

Investors

  • Ava Investors lead
  • Leclercq American Capital

Preparing a similar round?

The diagnostic shows you the instruments and investors that fit your stage.

Start the diagnostic